1.MRSA Infection in ICU:Investigation and Analysis of Nine Patients
Rui WANG ; Yihong ZHAO ; Yunkun HUANG ; Yun ZHAO
Chinese Journal of Nosocomiology 2006;0(02):-
OBJECTIVE To investigate and analyze the reasons of nosocomial infection(NI) in patients in intensive care unit( ICU),to find effective countermeasures for preventing NI and reducing the incidence rate of NI in ICU,and to enhance the management of ICU.METHODS All data of patients who suffered MRSA in ICU from Dec 2005 to Feb 2006,were analyzed by prospective monitoring and retrospective studies.RESULTS The nine patients were with lower respiratory tract.All were infected by the same MRSA.The same MRSA strain was found from hand,mouth and nose among the treating doctor and nurses based on the sample-analysis.CONCLUSIONS The incidence rate of NI in ICU is much higher than that in other departments.Risk factors depend on the severity of underlying diseases,invasive procedure,the quality of disinfection and sterilization,the incorrect use of the antibiotic,and patients′ immunity status especially among elderly.The key way to reduce incidence rate of NI is to take comprehensive measures and strengthen the antibiotic management.
2.Clinical Study on Feisu Granules for the Treatment of Acute Exacerbation of COPD with Syndrome of Phlegm-heat and Blood Stasis of Lung
Yunkun CHEN ; Qin LI ; Enyao WEI ; Feng ZHANG ; Jie WANG ; Xiuhua LI ; Huang LIU
Chinese Journal of Information on Traditional Chinese Medicine 2024;31(4):170-174
Objective To observe the clinical efficacy of Feisu Granules,and its effects on quality of life,coagulation and immune function in acute exacerbation of chronic obstructive pulmonary disease(AECOPD)with syndrome of phlegm-heat and blood stasis of lung.Methods Totally 120 AECOPD patients were divided into observation group and control group according to random number table method,with 60 cases in each group.The control group was given conventional Western medicine treatment,and the observation group received Feisu Granules treatment on the basis of the control group,one bag each time,three times a day,orally.The treatment for both groups lasted for 7 d.The clinical efficacy of both groups were observed.TCM symptom scores,St.George's respiratory questionnaire(SGRQ)score,coagulation function indexes(fibrinogen,D-dimer),and immune function indexes(CD4+,CD8+,CD4+/CD8+)of both groups were compared.The side effects were observed.Results The total effective rate in the observation group(93.10%)was significantly higher than that of the control group(79.66%),with statistical significance(P<0.05).Compared with before treatment,TCM symptom scores,scores of cough,wheezing,venous congestion,and SGRQ score decreased in both groups after treatment(P<0.05);after treatment,the observation group had lower above scores than the control group(P<0.05).Compared with before treatment,both groups showed a decrease in plasma fibrinogen and D-dimer levels after treatment(P<0.05);after treatment,the observation group showed lower levels of plasma fibrinogen and D-dimer compared with the control group(P<0.05).Compared with before treatment,the peripheral blood CD4+ and CD4+/CD8+ levels in both groups significantly increased after treatment,while CD8+ levels significantly decreased(P<0.05);after treatment,the peripheral blood CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group,while CD8+ was lower than those in the control group(P<0.05).Neither group had any drug-related side effects.Conclusion On the basis of conventional Western medicine,the combination of Feisu Granules in the treatment of AECOPD with syndrome of phlegm-heat and blood stasis of lung can significantly improve clinical efficacy,improve patient quality of life,facilitate coagulation function recovery,and enhance cellular immune function.
3.Association of metabolic associated fatty liver disease with carotid atherosclerotic plaque and stenosis
Yingdie ZHU ; Zhijiao ZHANG ; Guilin ZHANG ; Yunkun GAO ; Mengyao ZHENG ; Hua HUANG ; Gongfang ZHAO
Journal of Clinical Hepatology 2024;40(8):1591-1597
ObjectiveTo investigate the association between metabolic associated fatty liver disease (MAFLD) and carotid atherosclerotic plaque. MethodsA total of 1 107 patients who were hospitalized in The Second Affiliated Hospital of Kunming Medical University from July, 2014 to December, 2022 were enrolled, and all patients underwent abdominal ultrasound and CT angiography of the head and neck arteries. Baseline data and clinical diagnosis were collected, and the patients were divided into MAFLD group with 499 patients and non-MAFLD group with 608 patients based on medical history, clinical tests, and imaging findings. According to the CT value, carotid plaques were classified into calcified plaques, non-calcified plaques, and mixed plaques. According to the NASCET criteria, carotid stenosis was categorized as normal vessel, slight stenosis, mild stenosis, moderate stenosis, and severe stenosis/occlusion. The independent-samples t test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U rank sum test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between two groups. Univariate and multivariate Logistic regression analyses were used to investigate the influencing factors for carotid atherosclerosis. ResultsCompared with the non-MAFLD group, the MAFLD group had a significantly higher proportion of patients with calcified plaques (74.3% vs 63.3%, P<0.05), non-calcified plaques (27.1% vs 17.1%, P<0.05), or mixed plaques (27.3% vs 20.7%, P<0.05), as well as a significantly higher proportion of patients with mild stenosis (50.9% vs 44.9%, P<0.05), moderate stenosis (14.6% vs 8.4%, P<0.05), or severe stenosis/occlusion (6.6% vs 3.5%, P<0.05). The univariate logistic regression analysis showed that MAFLD was a risk factor for calcified carotid plaques, non-calcified plaques, and mixed plaques, and it was also a risk factor for mild stenosis, moderate stenosis, and severe stenosis/occlusion of the carotid artery (all P<0.05). After adjustment for confounding factors, the multivariate Logistic regression analysis showed that MAFLD was an independent risk factor for calcified plaque, non-calcified plaque, mixed plaque, and moderate stenosis of the carotid arteries (all P<0.05). ConclusionMAFLD is an independent risk factor for moderate stenosis, calcified plaques, non-calcified plaques, and mixed plaques of the carotid arteries.
4.Knockdown of PGC1α suppresses dysplastic oral keratinocytes proliferation through reprogramming energy metabolism.
Yunkun LIU ; Nengwen HUANG ; Xianghe QIAO ; Zhiyu GU ; Yongzhi WU ; Jinjin LI ; Chengzhou WU ; Bo LI ; Longjiang LI
International Journal of Oral Science 2023;15(1):37-37
Oral potentially malignant disorders (OPMDs) are precursors of oral squamous cell carcinoma (OSCC). Deregulated cellular energy metabolism is a critical hallmark of cancer cells. Peroxisome proliferator-activated receptor-gamma coactivator-1 alpha (PGC1α) plays vital role in mitochondrial energy metabolism. However, the molecular mechanism of PGC1α on OPMDs progression is less unclear. Therefore, we investigated the effects of knockdown PGC1α on human dysplastic oral keratinocytes (DOKs) comprehensively, including cell proliferation, cell cycle, apoptosis, xenograft tumor, mitochondrial DNA (mtDNA), mitochondrial electron transport chain complexes (ETC), reactive oxygen species (ROS), oxygen consumption rate (OCR), extracellular acidification rate (ECAR), and glucose uptake. We found that knockdown PGC1α significantly inhibited the proliferation of DOKs in vitro and tumor growth in vivo, induced S-phase arrest, and suppressed PI3K/Akt signaling pathway without affecting cell apoptosis. Mechanistically, downregulated of PGC1α decreased mtDNA, ETC, and OCR, while enhancing ROS, glucose uptake, ECAR, and glycolysis by regulating lactate dehydrogenase A (LDHA). Moreover, SR18292 (an inhibitor of PGC1α) induced oxidative phosphorylation dysfunction of DOKs and declined DOK xenograft tumor progression. Thus, our work suggests that PGC1α plays a crucial role in cell proliferation by reprograming energy metabolism and interfering with energy metabolism, acting as a potential therapeutic target for OPMDs.
Humans
;
Carcinoma, Squamous Cell/metabolism*
;
Cell Proliferation
;
DNA, Mitochondrial
;
Energy Metabolism
;
Glucose
;
Mouth Neoplasms/metabolism*
;
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/metabolism*
;
Phosphatidylinositol 3-Kinases
;
Reactive Oxygen Species